Emma Hitt Nichols, PhD

Although the need for novel approaches to treat patients with TP53-mutated acute myeloid leukemia remains urgent, cautious optimism may be in order given recent data from clinical trials and upcoming studies.

Findings from several recent studies help shed more light on this class of agents, including novel combinations and development of second- and third-generation mTOR inhibitors.

Immune checkpoint inhibitors an induce resistance through activation of additional immune checkpoints such as LAG-3. Research around LAG3 will be important for the future.

Although osimertinib has been shown to overcome T790M-mediated mutations in the second-line setting, as with other EGFR tyrosine kinase inhibiors progression on osimertinib is inevitable.

During a virtual Targeted Oncology Case-Based Roundtable event, Timothy F. Burns, MD, PHD, discussed the treatment of non–small cell lung cancer based on clinical trial research.